How Will Human Genome Evolve From Here?
The news drove Human Genome shares up 226.2% to $10.83 in recent trading. Shares of Benlysta partner GlaxoSmithKline (GSK) were up 3.5% to $37.63.
Thoughts and observations stemming from the announcement:
The big question for Human Genome is whether the success in the first phase III study of Benlysta predicts a win in the second phase III study, results of which will be announced in November. The positive BLISS-52 study enrolled patients primarily in Asia, South America and Eastern Europe. The study still under way, known as BLISS-76, is treating patients mainly from North America and Europe. Other than that, the studies are largely identical.The placebo effect in the BLISS-52 was high (44% of placebo patients responded), so with treatments of lupus patients generally better in Western countries, will this hurt Benlysta's chances in BLISS-76? Human Genome officials spent a good amount of time addressing this question on the company's conference call this morning. Simply put, the company is confident that BLISS-52's success bodes well for BLISS-76 results in November. The evidence to back up that confidence is substantial. The results from BLISS-52 were very strong, so the drug has a lot of wiggle room just in case, for instance, placebo patients perform even better. Human Genome deserves a lot of credit for a well-designed study, including conceiving a novel primary endpoint that seems to have finally cracked lupus where previous studies failed.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV